America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2025 #36 **November 17, 2025**

INSIDE:

The Perceptions of Deferred Blood Donors Regarding False-positive Screening Results for Infectious Diseases Explored

A paper published in *Vox Sanguins* by researchers in the Netherlands reported on the findings of a study that sought to, "analy[z]e the perceptions of Dutch deferred blood donors regarding false-positive screening (FPS) result communication, and compares these with [existing] European blood establishment strategies."

The authors explained that interview and survey topics were "based on" the Health Belief Model (HBM), which outlines key factors influencing health behavi[o]r. Individuals included in the study were, "whole-blood (WB) donors with two FPS results for HIV-1, HIV-2, hepatitis C virus (HCV), hepatitis B surface antigen, or *Treponema pallidum*, along with a deferral letter issued between April and October 2023. [Of] 54 initial donors, 31 met the inclusion criterion, and 20 were selected based on proximity. Thirteen responded to the invitation, and 10 completed the interviews. [The study was conducted] from March to July 2024 at Sanquin Blood Supply. In-depth interviews with deferred donors, guided by the HBM and open-ended questions, were conducted in Dutch [and] lasted 30–45 minutes."

The researchers found that, "[p]articipants remained committed to donating, driven by altruism and moral duty or influenced by family or profession. Most valued patient safety and praised Sanquin's procedures, with trust even increasing in some cases. Deferrals did not change intention, as participants viewed donations as an essential public good. [Most participants experienced] negative emotions, including disappointment and confusion, due to the sudden deferral and lack of prior notification. A few, however, expressed understanding, reassurance, and satisfaction."

Additionally, the study discovered that, [most participants preferred reminders] after the deferral period, expressing difficulty remembering the date or breaking routine. They feared this might reduce their return despite their intention to donate again."

Also, the authors noted that, "[m]ost participants fav[o]red receiving FPS results via letter, valuing its personal touch and effectiveness, while acknowledging that personal contact with everyone is not feasible. However, some preferred phone calls, citing concerns about lost or impersonal letters. Participants stressed the need for clearer, more detailed explanations about FPS results and deferral status. While letters or phone calls were preferred, some wanted follow-up phone calls after receiving the letter. Participants recommended informing new donors about FPS

(continued on page 2)

The Perceptions of Deferred Blood Donors Regarding False-positive Screening Results for Infectious Diseases Explored (continued from page 1)

results and deferrals through letters, website updates, and intake interviews. Some suggested addressing FPS results only when relevant, to avoid confusion."

A comparison of the study's findings and the results from a European Blood Alliance institutional member survey discovered that 10 blood establishments, "inform donors after the first FPS result, four after the second and others at different stages. Fourteen use letters and phone calls; others use urgent convocations, delay contact or do not notify. Sixteen do not study donor reactions; two report mixed responses. Eleven apply temporary or permanent deferral[s], with differing re-entry rules. Support includes phone contact from eight, counse[l]ing from four and a medical helpline from one. COVID-19 led one establishment to shift from in-person contacts to letters and phone calls."

The researchers explained that the study results suggest, "[t]here is a need for blood establishments to develop strategies to reduce this emotional impact. Participants expressed irritation at the lack of details in their deferral letter, leading to negative emotions. [W]hile Sanquin Blood Supply strives for transparency, there is concern that explicitly mentioning specific tests such as human immunodeficiency virus (HIV) might lead to incorrect associations with serious conditions, which they seek to avoid. Sanquin Blood Supply informs donors after a second FPS result, unlike most EBA members who notify after the first. Although this approach aims to reduce unnecessary concern, it leads to confusion and distress among Dutch donors, who feel blindsided by the suddenness. Participants suggested that earlier notification could reduce the emotional impact, by framing it as likely due to random or laboratory errors, making a second result less unexpected."

The paper concluded that, "while some Dutch donors found Sanquin's deferral letters clear, most experienced confusion and distress, highlighting the need for improved communication. Improving clarity, implementing follow-up procedures, and adopting EBA practices are crucial for refining the deferral process and improving donor perceptions, benefiting both donors and the blood supply system."

Citation: Beckman, J.E., Padilla, N.D., van der Woud, A. *et al*. "Perceptions of deferred blood donors regarding false-positive screening results for infectious diseases and European blood establishment strategies." *Vox Sanguinis*. 2025.

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $420

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

Blood Community Welcomes HHS ASH in Joint Letter

America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross have sent a joint letter to Dr. Brian Christine, congratulating him on his new role as the Assistant Secretary for Health (ASH) at the U.S. Department of Health and Human Services (HHS). In the joint letter, the organizations expressed their readiness to meet with Dr. Christine and eagerness to discuss, "opportunities to continue our collaboration regarding supporting interagency efforts related to blood safety and availability, the AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism, and the National Blood Collection and Utilization Survey (NBCUS)."

Specifically, ABC, AABB, and the American Red Cross explained that, "we stand ready to support you and provide you with any information, technical assistance, and contact information that might be needed as you take over the responsibilities of liaising with relevant agencies and the blood community. [We respectfully request] that you ensure the Office of the Assistant Secretary for health (OASH) representative on the Task Force continues to have the ability to highlight issues related to blood safety and availability with the Blood, Organ, and Tissue Senior Executive Council (BOTSEC) and agencies throughout the federal government. [We recommend] that the OASH continue its critical role in supporting the development and release of the NBCUS data." We will continue to provide updates on our advocacy efforts as they become available. Please contact us with questions.

(Source: Blood Community Joint Letter, 11/10/25)

WORD IN WASHINGTON

The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) have announced the appointment of Richard Pazdur, MD as director of the Center for Drug Evaluation and Research (CDER). According to a news release from FDA, Dr. Pazdur is, "a 26-year veteran of the FDA and the founding director of its Oncology Center of Excellence. A renowned regulatory innovator, Dr. Pazdur developed an integrated approach for cross-center coordination of oncology product review to expedite the development of novel cancer therapies. He also led the agency's launch of a series of initiatives that streamlined oncology drug approvals, access, and labeling: Project Orbis to provide a framework for concurrent submission and review of oncology products among international partners, Project Facilitate to support oncology professionals in completing expanded access requests for cancer patients, and Project Renewal to update the prescribing information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date. [Before joining the FDA,] Dr. Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received his bachelor's degree from Northwestern University, his MD from Loyola Stritch School of Medicine, and completed clinical training at Rush-Presbyterian St. Luke's Medical Center and the University of Chicago Hospitals and Clinics. Dr. Pazdur has published more than 800 articles, book chapters, and abstracts, and two medical oncology textbooks. Dr. Pazdur will continue to serve as director of the Oncology Center of Excellence until a successor is named."

(Source: FDA News Release, 11/11/25)

The FDA announced on October 28th that the agency's Adverse Event Reporting System (FAERS) has, "received increased reporting of allergic/hypersensitivity type reactions following infusion of specific lots of Immune Globulin Intravenous (IGIV) and/or and Immune Globulin Subcutaneous (IGSC). ADMA Biologics is the manufacturer of the products:

- Asceniv lot # 239825 with an expiration date of 8//31/27;
- Bivigam lot # 237452 with an expiration date of 10/31/27.

(continued on page 4)

WORD IN WASHINGTON (continued from page 3)

FDA explained that, "reports included serious adverse events, some of which were considered severe, requiring treatment with epinephrine, steroids, and/or admission to the emergency room or hospital. Though hypersensitivity and anaphylactic/anaphylactoid reactions are a known risk with immune globulin products, the increased reporting of hypersensitivity reactions to these lots presents heightened safety risks for patients." The agency is recommending the following actions:

- "[p]lease examine your stock immediately to determine if you have any vials from these lots;
- [i]f you have product from these lots, please cease use immediately; [and]
- [i]f you have questions about a lot, please contact the manufacturer."

Continuous monitoring and assessment of the safety of all biological products, including IGIV and/or IGSC products, is an FDA priority and we remain committed to informing the public when we learn new information about these products. To report suspected adverse events, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The Cybersecurity & Infrastructure Security Agency (CISA), in collaboration with the Federal Bureau of Investigation, Department of Defense Cyber Crime Center, Department of Health and Human Services, and international partners, has disseminated, "an updated joint Cybersecurity Advisory (#StopRansomware: Akira Ransomware) to provide network defenders with the latest indicators of compromise, tactics, techniques, and procedures, and detection methods associated with Akira ransomware activity." The November 13th agency communication, "reflects new findings [highlighting] Akira ransomware's evolution and continued threat to critical infrastructure sectors. Akira ransomware threat actors, associated with groups such as Storm-1567, Howling Scorpius, Punk Spider, and Gold Sahara, have expanded their capabilities, targeting small and medium-sized businesses as well as larger organizations across sectors including Manufacturing, Educational Institutions, Information Technology, Healthcare, Financial, and Food and Agriculture." Additionally, CISA noted in the announcement that the agency and its partners, "strongly encourage organizations to apply patches for known vulnerabilities, especially those affecting VPN products and backup servers, and enforce multifactor authentication for all remote access services. Organizations should monitor unauthorized domain account creation and unusual network activity while deploying endpoint detection and response solutions to enhance security."

(Source: CISA Communication, 11/13/25)

PEOPLE

Versiti recently announced that **Lynn Malec, MD, MSc** has been promoted to program director of the Comprehensive Center for Bleeding Disorders (CCBD) and Pharmacy, located at Children's Hospital of Wisconsin. The news release stated that, Dr. Malec's promotion, "recognizes her exceptional service to patients, including her leadership in bringing gene therapy for hemophilia B to Versiti, as well as her internationally renowned research contributions. Since joining Versiti in 2016, Dr. Malec has led strategic initiatives that translate scientific breakthroughs into accessible patient care. She developed and launched Versiti's gene therapy program, which has successfully treated two patients with HEMGENIX, an FDA-approved gene therapy for hemophilia B. The CCBD is among the first centers in the United States to administer this breakthrough treatment." Matthew Anderson, MD, executive vice president of Medical Sciences Institute and chief medical officer at Versiti, added in the news release, "Dr. Malec is the ideal combination of clinical and research excellence; she exemplifies our mission. he recognizes transformative opportunities early, focuses on patients as whole people, and delivers world-class care." Her research credentials include being, "a first-author publication in the New England Journal of Medicine reporting clinical trial results of a novel hemophilia A therapy. She has also secured National Institutes of Health R01 grant funding and established the Joan Gill Pilot Award to support collaborative research in hematology."

(Source: Versiti News Release, 10/16/25)

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

INPUT REQUESTED: Help Shape ABC's 2026 Advocacy Agenda

The development of America's Blood Centers' (ABC) 2026 Advocacy Agenda is officially underway, and we are encouraging all ABC members to share your input through our 2026 ABC Advocacy Agenda Survey by December 5th. Each year, ABC updates its Advocacy Agenda to reflect the federal legislative and regulatory issues most critical to blood centers across the country. This process ensures that our priorities remain relevant, actionable, and aligned with the evolving needs of community blood centers. More information is available here. Please contact us with any questions.

ABC *Awards of Excellence* Nominations Are Open

ABC is now accepting nominations for the *29th Annual Awards of Excellence*. This program provides ABC members with the opportunity to offer national recognition and showcase the best and brightest in the blood donation community. This year we will recognize award winners at a lunch during the 2026 ABC Annual Meeting in Tucson, Ariz. March 9th-12th, where we can celebrate their achievements with fellow meeting attendees. Descriptions of each award are available here.

The following awards will be presented and are currently open for nominations:

- ABC Outstanding Blood Drive of the Year; (*drive must fall between Oct. 1, 2024 – Sept. 30, 2025)*
- Outstanding Public Relations Campaign;
- Corporation of the Year Award; and
- Larry Frederick Award.

ABC will also present the following discretionary awards:

- William Coenen President's Award;
- Blood Community Advocate of the Year Award; and
- Thomas F. Zuck Lifetime Achievement Award (click here for a list of past winners).

The Foundation for America's Blood Centers will present:

- ITxM Award for Excellence in Technical Operations.

ABC encourages all members to take advantage of this opportunity to recognize your supporters by submitting your nominations before Friday, November 28th. We are accepting up to three nominations per category from each member blood center. Nominations will be reviewed by an independent committee. Award recipients will be announced in January 2026. Travel and hotel expenses of recipients of the ABC *Awards of Excellence* are the responsibility of the nominating blood center.

The recipient of the ITxM Award for Excellence in Technical Operations will have their expenses covered by the Foundation for America's Blood Centers. Please contact us with questions.

(continued on page 6)

INSIDE ABC (continued from 5)

Celso Bianco Lectureship Nominations Are Open

The Dr. Celso Bianco Lecture Series is an endowment that funds the search, travel, lodging, and speaker fees to allow a blood banking industry expert to speak on a topic related to blood banking or transfusion medicine every year at the ABC Annual Meeting. This lecture series is an outstanding opportunity to honor the more than 40 years of Dr. Bianco's contributions and accomplishments as well as to recognize other leading blood banking and transfusion medicine experts and continue the cycle of knowledge transfer. You may submit a nomination or self-nominate by the November 28th deadline. A listing of previous lecturers is available. Please contact us with any questions.

INPUT REQUESTED: New and Noteworthy Sessions at ABC Annual Meeting

At the 2026 ABC Annual Meeting, March 9th-12th in Tucson, Ariz., we are excited to reintroduce our "Center Insight" sessions, now called "New and Noteworthy," to showcase the innovative work of our members. These sessions may cover various topics, such as donor and workforce strategies, innovative partnerships, new service offerings, research studies, and more.

ABC is a community of members, and we encourage you to share openly. Each presentation will last about 15 minutes and could become part of a panel or stand alone as a separate session. Please submit your ideas for consideration by November 28th.

Submit an Abstract for the 2026 ADRP Annual Conference

The call for 2026 ADRP Annual Conference presenters is open! You are encouraged to please share your knowledge, insights, and expertise with ADRP's global community in Minneapolis, Minn. May 14th-16th. The submission form can be started and revisited at your convenience prior to the January 5th submission deadline.

Sessions include abstract presentations and discussions (60 minutes), quick hits (25 minutes), and digital posters! Abstracts should include data and research findings, case studies, practical pilots, and innovative policy and practices. Desired topics include:

- donor recruitment, engagement, and retention;
- collaboration between blood center departments for best outcomes;
- collections: technical and operational topics;
- social media applications in blood centers/TikTok use/social interaction;
- marketing initiatives, earned media and public relations strategies;
- first-time donors;
- donor journey/donor management;
- social sciences and donor behaviors;
- artificial intelligence (AI) practices, policies, and implementations;
- industry innovations; and
- cellular therapies/biotherapies.

A webinar titled "Creating a Successful Presentation Application for 2026 Annual Conference" will take place on December 9th. Stay tuned for details on registering. Please contact us with any questions.

(continued on page 7)

INSIDE ABC (continued from 6)

SAVE THE DATE: SMT Journal Club Webinar Set for December 12th

The next ABC Scientific, Medical, and Technical (SMT) Journal Club webinar will take place on December 12th at 12 p.m. EST. The webinar is complimentary for all ABC members as this virtual event will review two scientific/medical articles followed by open discussion by participants, presenters, and article authors. The articles to be reviewed are listed below:

- The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis (*Transfusion Medicine*); and
- Collaboration is key: Case report of suspected Pseudomonas fluorescens transfusion-associated infection (*Transfusion*).

A Continuing Medical Education (CME) credit (1.0) is now offered for all ABC SMT Journal Club webinars upon completion of the activity and evaluation. Additional information and a link to registration will be available to ABC members soon. Please contact us with any questions.

October *Blood Bulletin* Available



The latest edition of *Blood Bulletin*, titled "Helping Patients Understand Potential Limitations of Directed Donation Requests" has been published. This issue of *Blood Bulletin* was written by: Teresa Nester, MD, Co-Chief Medical Officer at Bloodworks Northwest; Kirsten Alcorn, MD, Co-Chief Medical Officer at Bloodworks Northwest; Roni J. Bollag, MD, PhD, Laboratory Medical Director, National Blood Testing Collaborative and Augusta University Blood Bank; Nanci Fredrich, RN, BSN, MM, Transfusion Safety Officer, Versiti; Ruchika Goel, MD, MPH, CABP, Senior Medical Officer, Vitalant National Office; Daniela Hermelin, MD, Chief Medical Officer at ImpactLife; Kathleen Hopping, MS, Senior Director Regulatory Affairs, Vitalant; and D. Kip Kuttner, DO, Vice President and Medical Director at Miller-Keystone Blood Center. The authors of this publication disclose no conflicts. *Blood Bulletin* is reviewed and edited by the America's Blood Center (ABC) Scientific, Medical, and Technical Publications Committee.

Workforce Trends Survey Report Available

ABC has published the 2025 Workforce Trends Survey Report. This resource offers deep insights into compensation, benefits, human resources policies, turnover and retention rates, and workforce trends specific to blood centers. Those ABC member blood centers who participated in the Workforce Trends Survey can purchase the report at a discounted price (code required and has been emailed to authorized individuals) of $450 while non-participating blood centers can purchase the report at the full price of $900. This survey combines the previous Compensation & Benefits and Employee Turnover & Retention surveys. Please contact us with questions.

MEMBER NEWS

Gulf Coast Blood recently announced a strategic partnership with Delcon USA that aims to, "accelerate innovation in blood and cell collection, donor experience, and operational efficiency, helping to shape the future of the global blood and biotherapy industry." According to a joint news release, "[t]he collaboration establishes an action-oriented framework for both organizations to co-create, test, and scale high-impact solutions that enhance donor engagement, optimize collections, and potentially improve clinical and operational outcomes. [Under the agreement,] Gulf Coast Blood and Delcon will jointly pilot and commercialize

(continued on page 8)

MEMBER NEWS (continued from 7)

advanced solutions powered by the Delcon Ecosystem — a connected suite of technologies including the OpenChair AI engagement platform, DelcoNet data and device management system, Milano Mixer blood collection device, and Giotto Monza Extractor. The collaboration will focus on developing scalable innovations that not only benefit Gulf Coast Blood but also advance the broader global blood center community."

(Source: Joint News Release, 11/10/25)

Carter BloodCare recently held the official ribbon-cutting event for its newest donor center in Burleson, Texas, a rapidly growing suburb south of Fort Worth. The Carter BloodCare team was joined at the ceremony by several community and business leaders from Burleson. The Burleson Donor Center marks Carter BloodCare's 26th fixed-site donation location, where it accepts whole blood, double red cell, plasma, and platelet donations. Along with Carter BloodCare's mobile blood drives, the Burleson Donor Center provides a convenient site for residents to support fellow neighbors in need. Carter BloodCare officials noted that North Texas is currently one of the fastest growing population areas in the United States; the new donor center in Burleson is an important resource to meet the region's increasing requirements for lifesaving blood and blood components.

(Source: Carter BloodCare Announcement, 11/11/25)

Contributed by James Black, Senior Public Relations Specialist at Carter BloodCare

Stanford Blood Center in partnership with Stanford Medicine, and a Bay Area procurement organization played a pivotal role in helping to, "increase[e] the availability of donor hearts [and] also shif[t] the paradigm in heart transplantation with the innovation of the first beating-heart transplant in an adult using a donor heart after circulatory death with the support of an organ perfusion system." An article highlighting this achievement on the Stanford Health Care website noted that, "[o]rgan perfusion systems have expanded the pool of potential donor hearts. With mechanical perfusion, surgeons can use hearts from donors who have died from circulatory death — known as DCD (donation after circulatory death). Perfusion systems reanimate DCD hearts after they are removed from the donor, allowing them to continue pumping blood while being evaluated for transplant and transported to a recipient. Keeping a heart beating, rather than asleep on ice, improves both its assessment and preservation."

(Source: Stanford Health Care, "Stanford Medicine Surgeons Pioneer Beating-Heart Transplantation to Expand Donor Pool and Improve Outcomes," 9/19/25)

GLOBAL NEWS

The World Health Organization (WHO) is hosting a webinar titled: "WHO Guidance Implementing Patient Blood Management (PBM) to Improve Global Blood Health Status" on November 18th at 7 a.m. EST. Registration is open for the virtual event that will include: "Part 1: Introduction – An overview of the guidance, presented by one of the authors; [and] Part 2: Sharing Experiences – Presentations from clinicians on the implementation of PBM in various countries." In March 2025, WHO published the PBM guidance document which the agency described as being designed to, "facilitate the global implementation of PBM [using] the '8-model', a structured pathway for complex and comprehensive system implementation in large sectors including national health care systems [segmented into] three phases: preparing the

(continued on page 9)

GLOBAL NEWS (continued from 8)

national/jurisdictional health care system for PBM, conducting PBM pilot projects, and rolling out PBM nationally/jurisdictionally." The guidance document also includes toolkits that, "provide practical strategies and resources for managing iron deficiency, an[e]mia, blood loss and coagulopathy, ensuring comprehensive care across diverse health care settings."

(Source: WHO Announcement, 10/24/25)

Researchers in Finland have published a paper in *Vox Sanguinis* that aims to, "model the combination of delivery and demand of prehospital transfusion with drone logistics to support the future development of the Finnish blood supply chain." They explained that, "[i]n the simulation, events were managed using the following approach: each event within a drone's range was handled to ensure the fastest possible response. This involved optimizing the drone's route and schedule to minimize the arrival time at the event location. If the nearest drone was occupied at the time of an event, the system selected a quicker solution from two options: (i) queuing at the nearest blood distribution cent[er] (BDC) until the completion of the drone's current mission or (ii) dispatching an alternative available drone closest to the target location within range." The authors discovered that, "irrespective of the selected time limit, the number of BDCs and the drone's operational range are the most critical factors influencing patient reach. The drone's speed significantly impacts scenarios with the shortest time limits and has only a marginal effect with larger time limits. Additionally, it was observed that a smaller number of BDCs can largely be offset by increasing the drone's range. This finding is significant because enhancing a drone's range is much more cost-effective than increasing the number of BDCs. Furthermore, advancements in battery technology make extending the operational range more feasible." The researchers concluded that, "[w]hile our model is a simplified version of reality, it provides insight into how drones could be effectively used for delivering blood products. Developing a simulation model that considers local weather conditions, the possible maintenance delays at the BDC and trauma site, the availability of medical staff to use the delivered blood products on site and other important practical factors is essential to fully understand the potential and requirements of using drones in prehospital blood transfers. Such a simulation model could be applied to any geographic area with available data on estimated delivery needs. Additionally, this type of simulation model could be used to address more dynamic situations involving spatio-temporal changes in delivery needs, such as those caused by holiday seasons or catastrophic events."

Citation: Erästö, P. Milla, J., and Pappinen, J. *et al*. "Supplying whole blood with drones for prehospital transfusion at trauma sites in Finland: A simulation." *Vox Sanguinis*. 2025.

COMPANY NEWS

The **International Society of Blood Transfusion (ISBT)** has announced an update to the ISBT Blood Group Database. An email update from the ISBT Working Party for Red Cell Immunogenetics and Blood Group Terminology explained that, "[n]early eight years ago, we first envisioned replacing our Blood Group Allele PDF tables with a dynamic solution: an open-source electronic database, designed to keep pace with rapidly evolving knowledge. After extensive development alongside dedicated experts, that vision is now a reality.
This database offers many advantages over static PDF tables:

- [a]lways up to date –[the] web-based database is continuously updated, with new alleles and reclassifications available in monthly releases;
- [r]ich context and annotation – [i]ncludes variant details, predicted protein changes, genomic coordinates, and phenotype summaries;
- [s]treamlined allele submission – [s]ubmit new alleles directly through our guided online system for faster review and inclusion; [and]

(continued on page 10)

COMPANY NEWS (continued from 9)

- [p]rogrammatic access via API – [r]etrieve blood group data directly into your bioinformatics tools and pipelines without manual PDF parsing."

The database is designed to be a resource for serology/reference laboratory professionals, genomics researchers, and clinical molecular laboratory professionals.

(Source: ISBT Announcement, 11/12/25)

Terumo Blood and Cell Technologies (Terumo BCT) and **Santersus AG** are partnering, "to improve clinical outcomes for patients who become critically ill due to sepsis." A company news release described the collaboration as, "combin[ing] Santersus' first-in-class NucleoCapture blood purification technology with Terumo BCT's industry-leading Spectra Optia™ Apheresis System. Santersus' therapeutic device has been designated a Breakthrough Device by the U.S. Food and Drug Administration (FDA) based on its preclinical and early clinical data [and is] designed to selectively remove NETs from the blood plasma. [In this partnership,] Santersus will lead the pivotal NUC-CAP clinical study in the U.S., UK, and EU. Terumo BCT will support the clinical development of the research. Additionally, Terumo Ventures, the corporate venture capital arm of Terumo Corporation, is investing in Santersus' Series A financing round to accelerate the development of this technology."

(Source: Terumo BCT News Release, 11/12/25)

Kytopen Corp. and **Excellos, Inc.**, a cell therapy contract development and manufacturing organization (CDMO) and member of **Blood Centers of America (BCA)** are, "exploring a collaboration to advance non-viral cell therapy manufacturing technologies," according to November 12th news release. As part of the potential partnership, the companies will, "focus on assessing the compatibility of Kytopen's Flowfect Tx® platform with Excellos' donor-to-dose manufacturing model and deep cell characterization capabilities. Together, the companies aim to evaluate opportunities to enhance process consistency, scalability, and overall cell quality in the development of next-generation cell-based therapies," noted the announcement. "The initial work will focus on identifying areas of scientific and operational synergy, with the potential for future collaboration as development priorities converge. These proof of principle initiatives aim to generate deeper insights into the biological and process complexities that are not yet fully understood."

(Source: Kytopen Corp. News Release, 11/12/25)

BioMarin Pharmaceutical Inc. recently announced plans to "divest" Roctavian, its one-time advanced therapy treatment for adults with severe hemophilia, according to a 3rd quarter earnings news release. "As we focus on the business units aligned with our strategic priorities, today we are announcing the decision to pursue options to divest Roctavian and remove it from our portfolio," explained Alexander Hardy, president and chief executive officer of BioMarin Pharmaceutical Inc. in the news release. "We continue to believe Roctavian has an important role to play in the treatment of hemophilia A and are therefore evaluating out-licensing options for this innovative gene therapy. This decision is consistent with BioMarin's portfolio strategy and offers the most promising opportunity for ensuring continued patient access to Roctavian. [Specifically,] BioMarin plans to continue to make Roctavian commercially available in the U.S., Italy, and Germany until next steps are finalized. The company will continue to provide support and monitoring for people treated with Roctavian."

(Source: BioMarin Pharmaceutical Inc.10/27/25)

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2025

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** Registration is open. More information available here.

Dec. 9. **ADRP Webinar (Virtual): Creating a Successful Presentation Application for the 2026 Annual Conference.** More information is coming soon.

2026

Feb. 11-12. **4th Biennial International Plasma and Fractionation Association (IPFA) & EBA Symposium on Plasma Collection and Supply. Leuven, Belgium**. Registration is open. More information is available here.

Mar. 9-12. **2026 ABC Annual Meeting. Tucson, Ariz.** More information is coming soon.

May 14-16. **2026 ADRP Annual Conference. Minneapolis, Minn.** More information is coming soon.

June 8-9. **2026 ABC Advocacy Workshop. Washington, D.C.** More information is coming soon.

June 20-24. **International Society of Blood Transfusion (ISBT) 39th International Congress. Kuala Lumpur, Malaysia.** More information available here.

Oct. 4-7. **American Association of Tissue Banks (AATB) Annual Meeting. San Francisco, Calf.** More information available here.

Oct. 17-19. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Chief Scientific Officer. A national search is underway to recruit a recognized executive with exceptional vision and leadership abilities to become the next Chief Scientific Officer (CSO) of Gulf Coast Blood, headquartered in Houston, Texas. Reporting to the CEO, the CSO serves as the senior medical and scientific leader of Gulf Coast Blood. They are responsible for ensuring the highest standards in quality, clinical and operational excellence, and innovation across all laboratory and blood services, in addition to ensuring compliance with regulatory and accreditation standards. As a physician and strategic thought leader, the CSO drives the organization's quality and continuous improvement agenda while also serving as the medical expert to advise on future investments in the blood research investment fund which will advance translational initiatives. The CSO also oversees the scientific coordination of research partnerships, leads the medical advisory committee, serves as a part of the diligence team, and champions laboratory strategy and performance. This role is instrumental in aligning operational excellence with a forward-looking research and innovation agenda that supports the mission to save and sustain lives. To be considered for the role, inquiries, nominations, and applications (detailed CV for now) should be submitted electronically in confidence, to: charlotte.fredericks@kornferry.com.

(continued on page 12)

COMPANY NEWS (continued from page 11)

Vice President, Donor Outreach & Collections. ImpactLife is seeking a talented, passionate individual to join our leadership team as the **Vice President, Donor Outreach & Collections.** The VP is responsible for the Donor Outreach and Collections Division, ensuring consistent, adequate recruitment and retention of donors across our four-state geography, as well as the Marketing and Public Relations function, ensuring collaboration to ensure name recognition and support of donor recruitment efforts. Additional responsibilities include departmental budgeting and development of control systems to ensure organization objectives are met. Qualifications include bachelor's degree (preference given to candidates with a graduate degree) and minimum ten (10) years of leadership experience in a blood center, with oversight of donor recruitment or collections required. This position will be located at one of ImpactLife's main hubs: Davenport, Iowa; Springfield, Illinois; or Earth City, Missouri. Candidates should expect some travel both within the ImpactLife geography as well as nationally. At ImpactLife, we keep our mission, vision, and values at the forefront. As a leader you will lead, inspire, and mentor with clear communication leading to collaboration within your team and across the organization remaining focused on achieving our goals and fulfilling strategic initiatives. For more information including benefits and compensation, click here: Join Us!

Laboratory Testing Manager (Fresno, CA). The Laboratory Testing Manager will assist in managing and maintaining the day-to-day activities of all Laboratory Testing, including staff assets. The Laboratory Testing Manager will need to use their experience and judgment to ensure all quality control mechanisms in the laboratory comply with blood bank cGMP, FDA, CLIA, California Department of Health, and AABB regulations and standards. Must be comfortable in a fast-paced, dynamic team environment. The testing manager will report directly to the Director of Hospital Services and will collaborate with teams across the organization to ensure Laboratory Testing excellence in supplying and distributing safe blood products with the utmost quality and fiscal integrity. Persons filling this position are responsible for the oversight of outsourced testing, product quality control testing, and patient testing. Please click here to view the full job description and apply. **The deadline to apply is Friday, December 12, 2025.**

Quality Assurance and Compliance Specialist (San Diego Blood Bank). Make a Difference in Patients' Lives as a Quality Assurance and Compliance Specialist. The San Diego Blood Bank is seeking a Quality Assurance and Compliance Specialist II who will participate in maintaining a Quality Management System that supports the manufacture of FDA-regulated biologic blood, cell, and tissue products and other related regulatory activities. The Specialist ensures that the performance and quality of products conform to established standards and regulatory requirements. Reports to: Manager, Quality and Regulatory Affairs. Ideal candidates possess a bachelor's degree and at least four (4) years of experience in a Quality Assurance or Regulatory Affairs role that includes participation in FDA and State site inspections, experience with GMP requirements, application of quality assurance principles, and healthcare compliance within the biologics/pharmaceutical industry. **Click** HERE **for the full job description and to apply.**

Regional Director – Donor Operations. OneBlood seeks an experienced leader to direct all donor blood collection operations in Jacksonville, FL, ensuring compliance with regulatory and accreditation standards. This position oversees managers and supervisors, drives recruitment and collection goals, and works across departments to maintain a safe, sufficient blood supply. Responsibilities include improving operational processes, managing budgets and resources, and contributing to strategic planning to meet regional blood demands. **Qualifications:** Bachelor's degree required and 10+ years of management experience in a related field (or equivalent combination of education and experience). Strong leadership, analytical, and communication skills. Ability to travel up to 50 percent. We offer competitive salary, medical, dental, vision, life, and short/long-term disability programs to qualified employees. Paid time off (PTO and a 403b program are also available. Join our life saving Mission and apply here.

Associate Medical Director/Medical Director. Serve as the physician face of Versiti and Versiti Ohio, translating complex medical issues to educate other physicians, support staff, and the public. Opportunities in educational initiatives and clinical/applied research are available within Versiti and with our affiliated health systems. As part of the Versiti physician team you will have the opportunity to participate in clinical research projects with investigators at our world-renowned diagnostic laboratory and blood research institute. Joining our Medical Science Institute transfusion medicine physician team will provide you with a uniquely diverse and collaborative experience. Requirements: MD or DO Degree. Board certified/eligible in Blood Banking/Transfusion Medicine. At least three years of experience in blood center/transfusion medicine practice preferred. Licensed or eligible for an Ohio and Indiana; other state licenses may be required. Driver's License in good standing. Please click here to read the full job description and apply.

(continued on page 13)

COMPANY NEWS (continued from page 12)

Medical Laboratory Scientist – Transfusion Services (ARUP Laboratories, Salt Lake City, UT). ARUP Laboratories is seeking two Medical Laboratory Scientists to join our Transfusion Services team. Our Transfusion team is dedicated to delivering exceptional patient care by meeting the transfusion needs of University of Utah Hospitals and Clinics, as well as Huntsman Cancer Institute. Our mission is to ensure the right blood product reaches the right patient, at the right time, for the right reason. As a Level 1 trauma center, the University of Utah Hospital also provides solid organ and bone marrow transplants and serves as the burn center for the Mountain West. Our testing capabilities include type and screens, crossmatches, antibody identification using both manual and automated methods, and neonatal testing. This department offers a dynamic and fast-paced environment with diverse immunohematology experiences. Team members collaborate closely with residents, medical directors, and patient care teams and work in close proximity to patients. Schedules we have open are: On/7Off B week 10:00 PM – 8:30 AM & 7-On/7-Off A week 8:00 PM – 6:30 AM with training schedule of Monday – Friday, 8:00 AM – 4:30 PM. Posting numbers are: MEDIC01276 & MEDIC021408 located on our careers page at www.aruplab.com/careers.

Supervisor: Blood Bank and Transfusion Services (ARUP Laboratories, Salt Lake City, UT). ARUP Laboratories is seeking a results-driven Quality Supervisor to lead quality initiatives and provide regulatory expertise within our Donor Services. As a national nonprofit and academic reference laboratory, ARUP is at the forefront of diagnostic medicine. We are FDA, CAP, CLIA-, and ISO 15189-certified, with over 40 years of experience delivering exceptional quality and service. This is a unique opportunity to oversee and enhance quality systems in transfusion medicine. The Quality Supervisor will drive implementation of quality processes, standardization efforts, and best practices across the division. Key Responsibilities: Lead and coordinate quality initiatives for Donor Services and Transfusion Services. Support internal and external audits, risk assessments, and continuous improvement efforts. Serve as a liaison between ARUP and University of Utah staff to address quality issues and lead CAPA (Corrective and Preventive Actions). Oversee staff development, performance management, and promotions. What We're Looking For: Strong leadership and communication skills. Experience in donor services and/or transfusion services. A passion for quality and a commitment to organizational excellence. Interested candidates can apply at https://www.aruplab.com/careers.

Medical Director (Miller-Keystone Blood Center (MKBC)). Are you a mission-driven leader seeking to integrate patient care with public health while improving work-life balance? Join MKBC, where we save lives daily by supplying blood to hospitals across Pennsylvania (PA) and New Jersey (NJ). As **Medical Director**, you'll lead clinical oversight for transfusion medicine and ensure the safety, quality, and regulatory compliance of our blood services. You'll guide donor eligibility, review protocols, supervise lab operations, advise on complex medical issues, and collaborate with hospitals and public health partners. You'll also support staff education, represent MKBC in professional forums, and provide executive leadership to promote excellence and innovation. **Requirements:** M.D. or D.O. with Board Certification in Clinical Pathology, Internal Medicine, or Hematology. Board Certified or Eligible in Transfusion Medicine. Five to seven plus years in healthcare with a focus in blood banking. Medical licensure in PA & NJ. Strong knowledge of AABB, FDA, CLIA, and cGMP standards. **Benefits include:** Medical/Dental/Vision, FSA, Life Insurance, Disability, PTO, Retirement Plan & more. Make a lasting impact—apply today to join our lifesaving mission and see the full position description here https://hcsc.isolvedhire.com/jobs/1583606